KDR and neoplasm: Preliminary observations from the clinical trials with cabozantinib are promising, possibly due to the simultaneous targeting of cancer cell signal pathways (RET, MET, AXL), neutrophil function (MET, potentially KIT, and FLT3), and tumor angiogenesis (VEGFR2).52